Clopidogrel Bisulphate interactions
Checked as Clopidogrel in this data source.
Full monograph for Clopidogrel BisulphateCheck it against another medicine
Medicines
648 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Acalabrutinib | Major | Synergy | Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 3 sources — open the full entry |
| Apixaban | Major | Synergy | Concomitant use of apixaban with other agents that alter hemostasis such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), platelet aggregation… | 39 sources — open the full entry |
| Betrixaban | Major | Synergy | Concomitant use of betrixaban with other agents that alter hemostasis such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), platelet aggregation… | 39 sources — open the full entry |
| Cabozantinib | Major | Synergy | Coadministration of cabozantinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment… | 39 sources — open the full entry |
| Dabigatran Etexilate Mesylate | Major | Synergy | Drugs that can affect hemostasis such as glycoprotein IIb/IIIa inhibitors, thienopyridine antiplatelet agents, unfractionated and low molecular weight… | 3 sources — open the full entry |
| Dalteparin Sodium | Major | Synergy | Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the… | 7 sources — open the full entry |
| Daprodustat | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 2C8 may significantly increase the plasma concentrations and the risk of adverse effects associated with… | 1 sources — open the full entry |
| Dasatinib | Major | Synergy | Coadministration of dasatinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with… | 5 sources — open the full entry |
| Deferasirox | Major | Synergy | Coadministration with drugs that have known ulcerogenic or hemorrhagic potential may increase the risk of gastrointestinal bleeding associated with the use of… | 3 sources — open the full entry |
| Enoxaparin Sodium | Major | Synergy | Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the… | 7 sources — open the full entry |
| Eptifibatide | Major | Synergy | The combination of glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors and other drugs that inhibit platelet aggregation may significantly increase the risk of… | 5 sources — open the full entry |
| EsomeprazolebaseMUPS preparation | Major | Metabolism | Coadministration with proton pump inhibitors (PPIs) may reduce the cardioprotective effects of clopidogrel. The proposed mechanism is PPI inhibition of the… | 24 sources — open the full entry |
| Esomeprazole + Amoxicillin + Clarithromycin | Major | Metabolism · Unknown | Coadministration with proton pump inhibitors (PPIs) may reduce the cardioprotective effects of clopidogrel. The proposed mechanism is PPI inhibition of the…3 documented mechanisms | 26 sources — open the full entry |
| FluconazolebaseOphthalmic | Major | Metabolism | Coadministration with potent inhibitors of CYP450 2C19 may reduce the efficacy of clopidogrel, whose antiplatelet effect is dependent in part on bioactivation… | 17 sources — open the full entry |
| Fluoxetine Hydrochloride | Major | Metabolism | Coadministration with potent inhibitors of CYP450 2C19 may reduce the efficacy of clopidogrel, whose antiplatelet effect is dependent in part on bioactivation… | 17 sources — open the full entry |
| Fluvoxamine Maleate | Major | Metabolism | Coadministration with potent inhibitors of CYP450 2C19 may reduce the efficacy of clopidogrel, whose antiplatelet effect is dependent in part on bioactivation… | 17 sources — open the full entry |
| Fondaparinux Sodium | Major | Synergy | Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the… | 7 sources — open the full entry |
| Ibrutinib | Major | Synergy | Coadministration of ibrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 6 sources — open the full entry |
| Loperamide + Simethicone | Major | Metabolism | Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors)… | 12 sources — open the full entry |
| Loperamide Hydrochloride | Major | Metabolism | Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors)… | 12 sources — open the full entry |
| Lopinavir + Ritonavir | Major | Metabolism | Coadministration with cobicistat or ritonavir may reduce the efficacy of clopidogrel, whose antiplatelet effect is dependent in part on bioactivation to a… | 8 sources — open the full entry |
| Mifepristone | Major | Synergy | Concomitant use of anticoagulants may exacerbate mifepristone-induced vaginal bleeding in women. Prolonged, potentially heavy bleeding lasting approximately 9… | 4 sources — open the full entry |
| Mifepristone + Misoprostol | Major | Synergy · Unknown | Concomitant use of anticoagulants may exacerbate mifepristone-induced vaginal bleeding in women. Prolonged, potentially heavy bleeding lasting approximately 9…2 documented mechanisms | 4 sources — open the full entry |
| Naproxen Sodium + Esomeprazole Magnesium | Major | Metabolism · Others | Coadministration with proton pump inhibitors (PPIs) may reduce the cardioprotective effects of clopidogrel. The proposed mechanism is PPI inhibition of the…2 documented mechanisms | 25 sources — open the full entry |
| Nirmatrelvir + Ritonavir | Major | Metabolism | Coadministration with cobicistat or ritonavir may reduce the efficacy of clopidogrel, whose antiplatelet effect is dependent in part on bioactivation to a… | 8 sources — open the full entry |
| OmeprazolebaseMUPS tablet | Major | Metabolism | Coadministration with proton pump inhibitors (PPIs) may reduce the cardioprotective effects of clopidogrel. The proposed mechanism is PPI inhibition of the… | 24 sources — open the full entry |
| Pioglitazone | Major | Metabolism | Coadministration with clopidogrel may significantly increase the plasma concentrations of pioglitazone. The proposed mechanism is inhibition of the CYP450… | 24 sources — open the full entry |
| Pioglitazone + Glimepiride | Major | Metabolism | Coadministration with clopidogrel may significantly increase the plasma concentrations of pioglitazone. The proposed mechanism is inhibition of the CYP450…2 documented mechanisms | 26 sources — open the full entry |
| Pioglitazone + Metformin Hydrochloride | Major | Metabolism · Unknown | Coadministration with clopidogrel may significantly increase the plasma concentrations of pioglitazone. The proposed mechanism is inhibition of the CYP450…2 documented mechanisms | 24 sources — open the full entry |
| Ponatinib Hydrochloride | Major | Synergy | Coadministration of ponatinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with… | 3 sources — open the full entry |
| Prasugrel Hydrochloride | Major | Synergy | Concomitant use of prasugrel with other agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents… | 2 sources — open the full entry |
| Rabeprazole + Amoxicillin + Clarithromycin | Major | Metabolism · Unknown | Coadministration with proton pump inhibitors (PPIs) may reduce the cardioprotective effects of clopidogrel. The proposed mechanism is PPI inhibition of the…3 documented mechanisms | 26 sources — open the full entry |
| Rabeprazole Sodium | Major | Metabolism | Coadministration with proton pump inhibitors (PPIs) may reduce the cardioprotective effects of clopidogrel. The proposed mechanism is PPI inhibition of the… | 24 sources — open the full entry |
| Ramucirumab | Major | Synergy | Coadministration of ramucirumab and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Ramucirumab… | 2 sources — open the full entry |
| Regorafenib Monohydrate | Major | Synergy | Coadministration of regorafenib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment… | 5 sources — open the full entry |
| Repaglinide | Major | Metabolism | Coadministration with clopidogrel may significantly increase the plasma concentrations and hypoglycemic effects of repaglinide. The primary mechanism is… | 35 sources — open the full entry |
| Rivaroxaban | Major | Synergy | Concomitant use of rivaroxaban with other agents that alter hemostasis such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), platelet aggregation… | 1 sources — open the full entry |
| Tirofiban Hydrochloride | Major | Synergy | The combination of glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors and other drugs that inhibit platelet aggregation may significantly increase the risk of… | 5 sources — open the full entry |
| Trastuzumab Emtansine | Major | Synergy | Coadministration of trastuzumab emtansine with anticoagulant or antiplatelet drugs may potentiate the risk of hemorrhagic events associated with these drugs… | 40 sources — open the full entry |
| Tucatinib | Major | Metabolism | Coadministration with potent inhibitors of CYP450 2C8 may increase the plasma concentrations of tucatinib, which is primarily metabolized by the isoenzyme… | 1 sources — open the full entry |
| Warfarin Sodium | Major | Synergy | Concomitant use of clopidogrel and oral anticoagulants such as warfarin may increase the risk of bleeding. Although often prescribed (with or without low-dose… | 46 sources — open the full entry |
| Alteplase | Moderate | Synergy | Drugs that inhibit platelet function may increase the risk of bleeding when administered prior to, during, or after thrombolytic therapy. | 8 sources — open the full entry |
| Amiodarone Hydrochloride | Moderate | Metabolism | According to some of the manufacturers' labeling for amiodarone, ineffective inhibition of platelet aggregation has been reported in association with a… | 6 sources — open the full entry |
| Amlodipine Besilate + Atorvastatin | Moderate | Metabolism · Unknown | The concomitant administration of atorvastatin may reduce the metabolic activation of the prodrug clopidogrel and its antiplatelet effects. The proposed…2 documented mechanisms | 14 sources — open the full entry |
| Apalutamide | Moderate | Metabolism | Coadministration with potent inducers of CYP450 2C19 may enhance the metabolic activation of clopidogrel, resulting in increased platelet inhibition and… | 5 sources — open the full entry |
| Armodafinil | Moderate | Metabolism | Coadministration with inhibitors of CYP450 2C19 may reduce the efficacy of clopidogrel, whose antiplatelet effect is dependent in part on bioactivation by the… | 21 sources — open the full entry |
| Aspirin | Moderate | Synergy | Clopidogrel has been shown to potentiate the inhibition of platelet aggregation due to aspirin. The safety of chronic administration of aspirin or other… | 2 sources — open the full entry |
| Aspirin + Dipyridamole | Moderate | Synergy · Unknown | Clopidogrel has been shown to potentiate the inhibition of platelet aggregation due to aspirin. The safety of chronic administration of aspirin or other…2 documented mechanisms | 2 sources — open the full entry |
| Atorvastatin + Ezetimibe | Moderate | Metabolism · Unknown | The concomitant administration of atorvastatin may reduce the metabolic activation of the prodrug clopidogrel and its antiplatelet effects. The proposed…2 documented mechanisms | 14 sources — open the full entry |
| Atorvastatin Calcium | Moderate | Metabolism | The concomitant administration of atorvastatin may reduce the metabolic activation of the prodrug clopidogrel and its antiplatelet effects. The proposed… | 14 sources — open the full entry |
Conditions
Conditions in which Clopidogrel Bisulphate needs care, as documented in this source.
Hemorrhage
MajorClopidogrel is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage.
1 source
- "Product Information. Plavix (clopidogrel)." Bristol-Myers Squibb (2001):
Liver Diseases
ModerateThe pharmacokinetic disposition of clopidogrel in patients with liver disease has not been established. Clopidogrel undergoes biotransformation to an active metabolite that has not yet been isolated and an inactive form that represents approximately 85% of circulating clopidogrel. The metabolic and therapeutic activity of clopidogrel may be altered in patients with hepatic impairment and should be administered cautiously in patients with severe hepatic dysfunction. Clinical monitoring of hepatic function and bleeding activity is recommended.
1 source
- "Product Information. Plavix (clopidogrel)." Bristol-Myers Squibb (2001):
Kidney Diseases
MinorClopidogrel is partially eliminated by the kidney. Approximately 50% of clopidogrel is excreted in the urine and 45% in the feces. Plasma concentrations of the inactive metabolite and the degree of platelet inhibition are reduced in patients with severe renal impairment (creatinine clearance of 5-15 mL/min). However, bleeding times in patients with severe renal impairment did not differ from those with normal renal function. No dosage adjustment is recommended for patients with compromised renal function.
1 source
- "Product Information. Plavix (clopidogrel)." Bristol-Myers Squibb (2001):